Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer

Eastern Mediterranean Health Journal

Volumn 6, Issue 2-3, 2000, Pages 475-482

  Al Alwan, N A S ^a   Al Kubaisy, W ^b   Al Rawaq, K ^a  

^a UNIVERSITY OF BAGHDAD   (Iraq)

^b AL NAHRAIN UNIVERSITY   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; BREAST TUMOR; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; IRAQ; MIDDLE AGED; NEEDLE BIOPSY; PHENOTYPE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TIME; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IRAQ; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034158130     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Marrazzo A et al. Immunocytochemical determination of estrogen and progesterone receptors in 219 fine-needle aspirates of breast cancer. Anticancer research, 1995, 15:521-6.
2. Bradbeer JW. Primary tamoxifen treatment of breast cancer in elderly women. In: Anti-estrogens in oncology - past, present and prospects. Proceedings of the International Symposium of Hormonotherapy. Bologna, International Symposium of Hormonotherapy, 1985: 139-45.
3. Baum M et al. Current controversies in the role of antiestrogens in the treatment of carcinoma of the breast. Proceedings - Royal Society of Edinburgh, Section B: Biology, 1989:221-9.
4. Koss LG. Diagnostic cytology and its histopathologic bases, 4th ed. Philadelphia, Lippincott, 1992:1293-314.
5. Al-Alwan NAS. Clinicocytopathological evaluation of nuclear DNA ploidy and hormone receptor contents of breast tumours [Thesis]. Baghdad, College of Medicine, University of Baghdad, 1998:140-3.
6. Hayword JL, Carbone PP, Heuson JC. Assessment of response to therapy in advanced breast cancer. European journal of cancer, 1977, 13:89-94.
7. Rutqvist LE. Breast cancer registry, Stockholm, Gotlandregionen, 1977-1992. Stockholm Gotland, Onkologiskt Centrum, 1996.
8. Li BD et al. Estrogen and progesterone receptors: concordance between primary and recurrent breast cancer. Journal of surgical oncology, 1994, 57: 71-99.
9. Wilking N et al. Steroid receptor levels in breast cancer: relation with age and menopausal status. Acta oncologica, 1989, 28:807-10.
10. Nixon AJ et al. Relationship of patients' age to pathologic features of the tumor and prognosis for patients with stage I and II breast cancer. Journal of clinical oncology, 1994, 12:888-94.
11. McCarty KS et al. Comparison of sex steroid receptor analysis and carcino-embryonic antigens with clinical response to hormone treatment. Cancer, 1980, 46:2846-50.
12. Cvitkovic FB, Fandi A, Rouesse J. Breast cancer: the role of haemopoetic growth factors. Consultant series 5. Saint Claude, France, Centre René Huguenin, 1996:5-19.
13. Maass H et al. The problem of non-responding estrogen-receptor-positive patients with advanced breast cancer. Cancer, 1980, 46:2835-7.
14. Hamilton A, Piccart M. Adjuvant therapy for breast cancer. In: Proceedings of the 23rd Congress of the European Society for Medical Oncology. Athens, Congress of the European Society for Medical Oncology, 1998:45-50.
15. Cuzick J, Wang DY. The prevention of breast cancer. Lancet, 1986, 1(8472): 83-6.
16. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 1998, 351(9114):1451-67.